Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ANXA1

ANXA1

Basics

Aliases:
This biomarker is also known as:
  • Chromobindin-9,
  • Annexin-1,
  • ANX1,
  • p35,
  • Lipocortin I,
  • Annexin I,
  • Phospholipase A2 inhibitory protein,
  • Calpactin II,
  • LPC1,
  • Annexin 1,
  • Annexin A1,

Description…

Annexin 1 belongs to a family of calcium-dependent phospholipid binding proteins which are preferentially located on the cytosolic face of the plasma membrane. Annexin I protein has an apparent relative molecular mass of 40 kDa, with phospholipase A2 inhibitory activity. Since phospholipase A2 is required for the biosynthesis of the potent mediators of inflammation, prostaglandins and leukotrienes, annexin I may have potential anti-inflammatory activity. Annexin 1 also promotes membrane fusion and is involved in exocytosis. It seems to bind from two to four calcium ions with high affinity.

Attributes

QA State: Accepted
Type: Protein
Short Name:
HGNC Name: ANXA1

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.

Supporting Study Data

The following studies/protocols provide evidence supporting ANXA1 indications for the Breast…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Lung

Attributes

Phase: Three
QA State: Under Review

Overview

Annexin 1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including Annexin 1.

Performance Comment

The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of Annexin 1 is ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting ANXA1 indications for the Lung…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

Biomuta

Mutation Statistics

Gene Name: ANXA1
UniProt Accession #: P04083
Mutated Sites Count: 46
Associated Pubmed ID Count 7
CancerDO Count 20
Affected Protein Function Sites Count: 5

View in BioMuta